Lazertinib — Drug Intelligence | 10 EU Trials

Filter these 10 trials by condition, phase, country and more.

Open in Search →

10 Registered trials

2 Recruiting

8 Completed trials

3 Sponsors

15 Countries

Phase III

Phase II

Other

Phase III: 4 Phase II: 5 Other: 1

Indications tested

Non-small cell lung cancer 5 Non-small cell lung cancer stage IV 1 Non-small cell lung cancer metastatic 1

Sponsors using this IMP

Janssen - Cilag International 8 ETOP IBCSG Partners Foundation 1 Yuhan Corp. 1

All trials

10 total

A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous… Recruiting

2025-520730-28-00 Phase II 9 countries Janssen Cilag International
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid … Recruiting

2023-505065-91-00 Phase II 4 countries Janssen - Cilag International
Randomized open-label Phase 2 trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adver… Ended

2023-505863-35-00 Phase II 3 countries Janssen - Cilag International
ETOP 18-21 AMAZE-lung: A clinical study exploring the effect of amivantamab and lazertinib plus bevacizumab treatment, in people diagnosed w… Ended

2024-512288-29-00 Phase II 4 countries ETOP IBCSG Partners Foundation
A Clinical Study of Lazertinib with Subcutaneous Amivantamab Compared with Intravenous Amivantamab in Patients with EGFR-mutated Advanced or… Ended

2024-512045-16-00 Phase III 6 countries Janssen Cilag International
A Clinical Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in … Ended

2023-506518-33-00 Phase III 12 countries Janssen - Cilag International
A Clinical Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients … Ended

2023-506576-27-00 Phase III 9 countries Janssen - Cilag International
A Phase 1, Open-label, Randomized, 2-Part, 2-Way Crossover Study in Healthy Adult Participants to Assess the Relative Bioavailability of Tab… Ended

2022-502814-99-00 1 country Janssen - Cilag International
Evaluation of Amivantamab Infusion Related Reaction Mitigation Ended

2023-506578-11-00 Phase II 2 countries Janssen - Cilag International
A study to test the efficacy and safety of Lazertinib in the treatment of patients with Locally Advanced or Metastatic Non-Small Cell Lung C… Ended

2024-514771-18-00 Phase III 2 countries Yuhan Corp.

Showing 1–10 of 10 trials

← All drugs A–Z